LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To determine the level of the drug tacrolimus in your blood in order to establish a dosing regimen, maintain therapeutic levels, and detect toxic levels
As soon as tacrolimus therapy begins, frequently at first, then at regular intervals to monitor concentrations over time
A blood sample drawn from a vein in your arm
The sample should be collected 12 hours after your last dose and immediately prior to your next dose or as directed by your healthcare practitioner.
Tacrolimus, also known as FK506, is an immunosuppressive drug that is given orally or intravenously to people who have had a kidney, liver, heart, or other organ transplant. It is a potent drug that helps to prevent rejection of the transplanted organ by the body. This test measures the amount of tacrolimus in the blood.
Normally, a person's immune system recognizes a new, transplanted organ as foreign and begin to attack it. Tacrolimus limits this response and helps to prevent organ rejection by inhibiting the activation of certain immune cells called T-lymphocytes.
The level of tacrolimus in the blood must be maintained within a narrow therapeutic range. If the concentration is too low, organ rejection may occur; if it is too high, then the person may experience symptoms associated with toxicity.
Dosages must be tailored to the individual. Often, people will begin with higher doses of tacrolimus at the start of therapy and then decrease the dose over the next few weeks.
Tacrolimus is usually taken twice a day at set intervals before or after meals. When a person takes a dose, the blood concentration rises and peaks within about 2 to 3 hours and then begins to slowly drop. The blood test is usually measured as a "trough level," meaning that sample collection is timed for 12 hours post-dose and/or immediately prior to the next dose, when the drug's level in the blood is at its lowest.
The tacrolimus test is used to measure the amount of the drug in the blood to determine whether the concentration has reached a therapeutic level and is below the toxic level. It is important to monitor levels of tacrolimus for several reasons:
A tacrolimus test is ordered frequently at the start of therapy, often daily when trying to establish a dosing regimen. Once dosages have been established and shown to be well tolerated, the frequency of tacrolimus testing may be decreased. The test is also performed when dosages are changed and whenever someone has symptoms that suggest side effects, toxicity, or organ rejection.
Signs and symptoms of tacrolimus toxicity vary according to the type of organ transplant and may include:
Monitoring at intervals is necessary as long as someone is taking tacrolimus.
A concentration that is higher than the established therapeutic range may increase the risk of associated toxicity, including damage to the kidneys and nerves. A concentration that is too low may lead to rejection of the transplanted organ. Side effects may be seen at any dosage but tend to be more severe with a higher tacrolimus level.
The therapeutic range established by a laboratory will depend on both the method used to measure the drug and the type of transplant. Results from different methods are not interchangeable. A healthcare practitioner will usually send samples sent consistently to the same laboratory and will be guided by that laboratory's therapeutic ranges.
A variety of drugs can increase or decrease tacrolimus levels in the blood. These include calcium channel blockers, antifungal drugs, macrolide antibiotics (such as erythromycin), protease inhibitors, chloramphenicol, and other immunosuppressants, anticonvulsants, and antimicrobials. Tell your healthcare practitioner about any other medications you take, especially cyclosporine, sirolimus, nelfinavir telaprevir, boceprevir, and amiodarone. Many other prescription drugs, grapefruit juice, and herbal supplements such as St. John's Wort can also interact with tacrolimus.
Topical tacrolimus may be used to treat a variety of skin conditions, such as eczema, that have not responded well to other medications. This topical use of tacrolimus is intended to be local, not systemic, and is not usually monitored.
Tacrolimus increases the risk of developing malignancies such as lymphoma and skin cancer, so sunlight should be avoided when taking this drug. It can also cause new onset diabetes, especially in African Americans and Hispanics so a healthcare practitioner may monitor a person's glucose levels. Tacrolimus may also cause QT prolongation, a condition that affects heart rhythm.
People should not alter their dose or the time that they take their dose without consulting with their healthcare provider. Tacrolimus should be taken consistently with respect to meals. Food, especially high-fat meals, can significantly reduce the bioavailability (amount of the drug that reaches the circulation) compared with fasting.
Women who are pregnant or planning to become pregnant should talk to their healthcare practitioner about associated risks.
Transplant recipients must take tacrolimus or a different immunosuppressant (or combination of drugs) throughout their life. Talk to your healthcare practitioner about the best choice for your condition. This choice may change over time.
Tacrolimus will usually be monitored by the transplant team that performed the transplant or by a healthcare practitioner who has specific knowledge of the condition or disease for which the drug is prescribed.
Yes, this is important information for them to have, partially because of drug interactions and partially because of the immunosuppressive action of tacrolimus. It can affect your ability to heal, to get vaccinations, and may increase your risk of developing certain cancers (such as skin cancers).
Sources Used in Current Review
2018 review performed by Manoj Tyagi, PhD. NRCC, FAACC, Medical Director, Captiva Lab.
Hesselink DA, et Al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014 Feb;53(2):123-39. doi: 10.1007/s40262-013-0120-3.
Kalt DA, Tacrolimus: A Review of Laboratory Detection Methods and Indications for Use. Lab Med. 2017 Nov 8;48(4):e62-e65. doi: 10.1093/labmed/lmx056.
(June 2016) Food and Drug Administration, Draft Guidance on Tacrolimus. Available pdf https://www.fda.gov/downloads/Drugs/.../Guidances/UCM506916.pdf. Accessed June 28, 2018.
Sources Used in Previous Reviews
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC. McMillin, G. and Hammett-Stabler, C. Chapter 39: Therapeutic Drug Monitoring, Pp 453-463.
(2007 April 1). Tacrolimus. MedlinePlus Drug Information [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601117.html. Accessed on 6/9/07.
Aradhye, S., et. al. (2006 December, Revised). Medicines for Keeping Your New Kidney Healthy. American Society of Transplantation [On-line information]. PDF available for download at http://www.a-s-t.org/files/pdf/patient_education/english/AST-EdBroKIDNEYMED-ENG.pdf. Accessed on 6/9/07.
(2006 July 1, Revised). Tacrolimus Topical. MedlinePlus Drug Information [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602020.html. Accessed on 6/9/07.
Howard, A. (2004 July 12). Long-Term Monitoring and Care of the Kidney Transplant Recipient. Medscape Transplantation 5(2), 2004 [On-line article]. Available online at http://www.medscape.com/viewarticle/481411. Accessed on 6/9/07.
Kim, J. Cyclosporine and Tacrolimus Toxicities. Kidney Transplant Program, Univ of Southern California Department of Surgery [On-line information]. Available online at http://www.kidneytransplant.org/article-cyclosporineandtacrolimustoxicities.html. Accessed on 6/9/07.
(© 2007). Tacrolimus. ARUP's Laboratory Test Directory [On-line information]. Available online at http://www.aruplab.com/TestDirectory/clinical_guide.jsp. Accessed on 6/16/07.
(© 2007). Tacrolimus. LabCorp's On-line Directory of Services and Interpretive Guide [On-line information]. Available online at http://www.labcorp.com/datasets/labcorp/html/chapter/. Accessed on 6/16/07.
(2006 April, Revised). Prograf. FDA MedWatch [On-line information]. PDF available for download at http://www.fda.gov/medwatch/SAFETY/2006/Apr_PIs/Prograf_PI.pdf. Accessed on 6/16/07.
(2007 April 1). Tacrolimus (Oral Route, Intravenous Route). Mayoclinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/drug-information/DR601851. Accessed on 6/10/07.
Woo, D. and James, W. (2005 May 24). Topical Tacrolimus: A Review of Its Uses in Dermatology. Medscape from Dermatitis 2005;16(1):6-21 [On-line article]. Available online at http://www.medscape.com/viewarticle/505242. Accessed on 6/9/07.
(2001). Therapeutic Drug Monitoring: Is it Important for Newer Immunosuppressive Agents? Medscape from Drug Ther Perspect 17(22):8-12, 2001 [On-line information]. Available online at http://www.medscape.com/viewarticle/414907. Accessed on 6/9/07.
Martindale, The Complete Drug Reference (Online information). Available online at http://www.thomsonhc.com/hcs/librarian/PFDefaultActionId/pf.PrintReady. Accessed August 2007.
(June 1, 2008) MedlinePlus Drug Information. Tacrolimus. Available online at http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601117.html. Accessed March 2011.
(February 1, 2011) Mayo Clinic. Tacrolimus. Available online at http://www.mayoclinic.com/health/drug-information/DR601851. Accessed March 2011.
(December 4, 2007) United Network for Organ Sharing. Transplant Living: Medications, Tacrolimus. AVailable online through http://www.transplantliving.org. Accessed March 2011.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, Pp 317-318.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. St. Louis: Elsevier Saunders; 2006, Pp 1279-1280.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC. McMillin, G. and Hammett-Stabler, C. Chapter 39: Therapeutic Drug Monitoring, Pg 453-463.
(September 8, 2008) Lemi L. Transplants, Liver. eMedicine article. Available online at http://emedicine.medscape.com/article/776313-overview. Accessed March 2011.
Prograf. Rx List. Available online at http://www.rxlist.com/prograf-drug.htm. Last reviewed September 23, 2013. Accessed February 26, 2014.
Patient Information. Prograf. Astellas Pharma Inc. Available online at http://www.prograf.com/Docs/13H057-PRG-WPI-PPI.pdf. Accessed February 26, 2014.
Tacrolimus (Oral Route). Mayo Clinic. Available online at http://www.mayoclinic.org/drugs-supplements/tacrolimus-oral-route/description/drg-20068314. Last updated December 1, 2013. Accessed February 26, 2104.